Altered/overexpressed MYB was responsible for breast and colon cancer sensitivity to the anti-IGF-1R antibody figitumumab, and the combination with ErbB family inhibitors such as cetuximab, dacomitinib (both in colon cancers), or trastuzumab (in breast cancers), as well as combination with the CDK4/6 inhibitor palbociclib or oxaliplatin (both in colon cancers) led to synergistic effects[187]. Here, MYB is linked to malignant colon neoplasm.